Pharmaceutical

FLU-SV-mRNA by Curevac for Influenza A Virus, H1N1 Subtype Infections: Likelihood of Approval

FLU-SV-mRNA is under clinical development by Curevac and currently in Phase I for Influenza A Virus, H1N1 Subtype Infections.

Dec 20, 2023 - 18:00
FLU-SV-mRNA is under clinical development by Curevac and currently in Phase I for Influenza A Virus, H1N1 Subtype Infections.
Read the original article

Tags:

Previous Article

NNC-05600004 by Novo Nordisk for Liver Diseases: Likelihood of Approval

Next Article

ND-10 ER by Theialife Sciences for Myopia: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Key Senate panel considers Medicare bonuses for hospitals that prevent drug shortages

STAT+: Key Senate panel considers Medicare bonuses for ...

Jan 26, 2024

NICE recommends Pfizer’s Ritlecitinib for alopecia areata treatment

NICE recommends Pfizer’s Ritlecitinib for alopecia area...

Feb 24, 2024

Signal: Fresh Tracks nears end of operations with plans for dissolution

Signal: Fresh Tracks nears end of operations with plans...

Sep 21, 2023